This constitutes a large and comprehensive report on the clinicalexperience and associated biomarker accuracy with a combination of traditional andnovel AKI biomarkers and the first to report a real-life setting clinicalimplementation and experience using NGAL testing in Canada. This evidence concerns the gene LCN2 and acute kidney injury.